Inspira Technologies Redefines Artificial Respiration with ART Device

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

For those with acute respiratory failure, sometimes risk-laden intubation or a medically-induced coma that is necessary for mechanical ventilation is the only treatment available.

But what if there was a less invasive option?

Inspira Technologies IINN IINNW)), is a medical device company in the respiratory care industry, aiming to change the status quo with a viable alternative to mechanical ventilation. This cost-effective, less invasive approach is called the ART device which offers early extracorporeal respiratory support.

The current mechanical ventilation method to address acute respiratory failure pose many potential risks and complications, including ventilator-induced lung injuries and pneumonia, Infections from bacteria build-up in the endotracheal tube (intubation), Collapsed lung due to high inflow pressure, Medically induced coma side effects (Pressure wounds & Muscle wastage) as well as longer hospital stays and patient readmissions. Not to mention, they all require weaning off of mechanical ventilation, which is quite a process. During the COVID-19 pandemic, the limits of this veteran technology were highlighted. As a result, the COVID has become a growth engine for bringing innovative respiratory technologies to the market.

However, with the ART, oxygen saturation levels are designed to be elevated and stabilized in both awake and breathing patients — all in one minute. It includes features to prevent both hemolysis and thrombosis, enriching around 200 ccs of blood at any given point in time. It also enhances blood circulation, removing carbon dioxide and bonding high concentrations of oxygen to the blood. Included is an external centrifugal pump that moves the blood outside the body in order to take the load off the lungs.

Essentially, the ART functions as an artificial lung and this early saturation elevation can work to reduce both hospitalization stays and treatment costs. In addition, it uses a semi-automated initiation system, with a single-click disposable cartridge for ease of use, without needing any specially trained staff for operation. Instead of being limited to the ICU, it can be used in a variety of healthcare settings for maximum reach.

Recently, the company contracted GlobalLogic, a Hitachi Group Company, for advanced digital product engineering services.  The contract represents progress towards the production phase of the ART device's "brain", a platform that is algorithm-enhanced.  In addition, the company developed and filed a patent application for a supportive device to be utilized with the ART device. The supportive device is aimed to allow for safe treatment and mobilization of cannulated patients. This is expected to provide the medical staff more flexibility in implementing treatment procedures as well as to enable the safe transfer of patients within and between hospitals and medical centers.

In creating the ART, Inspira Technologies continues to partner with leading medical centers, while armed with an experienced and knowledgeable team in the field of respiratory illness and intensive care. While COVID-19 brought acute respiratory failure to the center stage, with deaths from the syndrome increasing yearly and although human trials have not yet been conducted by the company ART is aimed to be a long-term alternative solution to traditional mechanical ventilation. Redefining artificial respiration is no small feat, but that is exactly what Inspira Technologies has set out to do. ART is positioned to change the current standard of care for those with acute respiratory failure, affecting millions of lives worldwide.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.